Curetis and BGI subsidiary MGI Tech plan to develop NGS-based diagnostics for microbial infections on the MGISeq instrument for the Chinese market.
The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
The company's Hong Kong laboratory was established in 2010 and was accredited by the College of American Pathologists in 2013.
A Complete Genomics-led team isolated and sequenced the genomes of 34 circulating tumor cells from a woman with metastatic breast cancer.
Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.
Scientists reported this week for the first time a Danish reference genome based on the de novo assembly of 150 genomes from 50 family trios.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.
BGI won't be selling the gene-edited miniaturized pigs it developed, according to Technology Review.
The partners will explore the possibility of building a sequencing hub at the university for conducting local population cohort studies and diagnostic testing.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.